Neuronetics, Inc. 2024 Q1 Form 10-Q Summary
Business Context and Reporting Period
Neuronetics is a commercial-stage medical technology company whose primary product is the NeuroStar Advanced Therapy System, a transcranial magnetic stimulation system used for major depressive disorder and other cleared indications. Revenue is generated from system sales, recurring treatment sessions, service and repair, rentals, and extended warranties.
This unaudited report covers the three months ended March 31, 2024, compared with the three months ended March 31, 2023. The company operated as one business segment and had 29,975 thousand common shares outstanding at March 31, 2024.
Financial Performance and Position
| Metric | Q1 2024 | Q1 2023 | Change |
|---|---|---|---|
| Revenue | $17.4 million | $15.5 million | Up 12% |
| Gross profit | $13.1 million | $11.4 million | Up 15% |
| Gross margin | 75.1% | 73.3% | Up 180 basis points |
| Operating loss | $6.9 million | $9.9 million | Improved $3.0 million |
| Net loss | $7.9 million | $10.5 million | Improved $2.6 million |
| Basic and diluted loss per share | $0.27 | $0.38 | Improved |
| Cash used in operating activities | $12.0 million | $15.2 million | Improved $3.2 million |
- U.S. revenue increased 12% to $16.8 million, while international revenue increased 8% to $0.6 million. International revenue remained 4% of total revenue.
- U.S. treatment-session revenue increased 22% to $13.0 million. Treatment sessions sold increased from 158,742 to 210,737, and active customer sites increased from 1,081 to 1,168.
- U.S. NeuroStar system revenue declined 14% to $3.3 million; systems sold declined from 49 to 40.
- Operating expenses declined 6% to $19.9 million: sales and marketing decreased 2%, general and administrative decreased 10%, and research and development decreased 16%.
- Interest expense increased 46% to $1.8 million, primarily reflecting higher debt and interest rates. Other income increased to $0.8 million, supported by interest income on money-market balances and notes receivable.
- Cash and cash equivalents were $47.7 million at March 31, 2024, down from $59.7 million at December 31, 2023. Total assets were $103.8 million and stockholders’ equity was $27.7 million.
- Accounts receivable increased to $17.5 million from $15.8 million at year-end, while the allowance for credit losses increased to $1.3 million from $0.8 million.
Material Changes Versus the Prior Comparable Period
- Revenue growth was driven primarily by recurring treatment-session volume and higher utilization, partially offset by lower system sales.
- Gross-margin expansion reflected the greater proportion of higher-margin treatment-session revenue.
- Lower operating expenses reduced the operating loss, although the company remained unprofitable.
- Operating cash burn improved year over year but remained substantial at $12.0 million. Investing activities provided $0.1 million, primarily from notes-receivable repayments, and financing activities provided no cash.
- Share count increased to 29,975 thousand from 29,092 thousand at December 31, 2023, primarily reflecting share-based award activity. Share-based compensation expense was $1.3 million versus $1.8 million in Q1 2023.
Debt, Liquidity, Outlook, and Risks
- The company had $60.0 million of principal borrowings outstanding under its Solar credit facility, reported at $59.4 million net of discounts and fees. The facility matures in March 2028; principal and interest payments are scheduled to begin in April 2026.
- On March 7, 2024, the lender waived covenant violations related to minimum net product revenue for January and February 2024 and amended the liquidity and revenue covenants. The company stated that it was in compliance with all covenants at March 31, 2024 and projected compliance going forward.
- Management believes cash and anticipated product revenue are sufficient to fund operations for at least 12 months from issuance of the financial statements. The company nevertheless continues to incur operating losses and expects losses in the near term.
- Management identified a target of achieving cash-flow break-even in the fourth quarter of 2024 and for full-year 2025; achievement is not assured.
- Sales and marketing expense is expected to remain broadly consistent with 2023, general and administrative expense relatively consistent, and research and development expense higher during 2024.
- Key risks include dependence on NeuroStar system adoption and treatment utilization, reimbursement and payer coverage, competition, product defects, customer concentration, regulatory and intellectual-property matters, credit-facility covenants, and the need to achieve sustainable cash flow.
- One customer represented 17% of Q1 2024 revenue and had $2.4 million of accounts receivable and $4.8 million of notes receivable outstanding at March 31, 2024.
- The company held a $4.8 million secured note receivable from Greenbrook TMS-related entities bearing interest at SOFR plus 7.65%. Collection and counterparty performance should be monitored.
- A $2.9 million Employee Retention Credit receivable was included in current assets. Management reported no material adverse legal proceedings and no material changes to previously disclosed risk factors.
Important Facts for Investors to Verify
- Whether treatment-session growth and active-site expansion continue to offset declining system sales.
- Compliance with amended minimum-revenue and liquidity covenants, particularly before principal payments begin in 2026.
- Cash-burn trends, the sufficiency of the $47.7 million cash balance, and progress toward Q4 2024 and full-year 2025 cash-flow break-even.
- Recoverability and payment status of the Greenbrook-related $4.8 million note receivable and the $2.9 million ERC receivable.
- Customer concentration, accounts-receivable aging, and the increased allowance for credit losses.
- Whether gross-margin gains persist as product mix, pricing, manufacturing costs, and reimbursement conditions change.